<DOC>
	<DOCNO>NCT00784654</DOCNO>
	<brief_summary>The main aim study evaluate long-term maintenance efficacy LDX administer child adolescent age 6-17 ADHD least 6 month</brief_summary>
	<brief_title>Double-blind , Placebo-controlled , Randomised Withdrawal , Extension , Safety Efficacy Study LDX Children Adolescents Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Subject 's parent legally authorise representative ( LAR ) must provide signature informed consent , must documentation assent ( applicable ) subject indicate subject aware investigational nature study require procedure restriction accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation complete studyrelated procedure . 2 . Subject parent/LAR willing able comply test requirement define protocol , include oversight morning dosing . Specifically , parent/LAR must available upon awaken , approximately 7:00AM , dispense dose test product duration study . 3 . Subject male female age 617 year inclusive time consent antecedent study ( SPD489325 ) . 4 . Subject satisfied entry criterion antecedent study ( SPD489325 ) , complete minimum 4 week doubleblind treatment , reach Visit 4 complete 1week posttreatment washout antecedent study ( SPD489325 ) , without experience clinically significant AEs would preclude exposure LDX . 5 . Subject must satisfactory medical assessment clinically significant relevant abnormality determine medical history , physical examination finding clinical laboratory test result . 6 . Subject blood pressure measurement within 95th percentile age , gender , height . 1 . Subject terminate SPD489325 noncompliance and/or experience SAE AE result termination antecedent study . 2 . Subject current , control ( require restrict medication ) uncontrolled , comorbid psychiatric diagnosis significant symptom severe comorbid Axis II disorder severe Axis I disorder ( Post Traumatic Stress Disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) symptomatic manifestation , agitate state , mark anxiety , tension , opinion examine clinician , contraindicate treatment LDX confound efficacy safety assessment . Comorbid psychiatric diagnosis establish Screening Visit ( Visit 1 ) antecedent study ( SPD489325 ) Screening interview KiddieSADSPresent LifetimeDiagnostic Interview ( KSADSPL ) additional module warrant result initial interview . Participation behavioural therapy permit provided subject receive therapy least 1 month time Baseline Visit ( Visit 0 ) antecedent study ( SPD489325 ) . 3 . Subject conduct disorder . Oppositional defiant disorder exclusionary . 4 . Subject concurrent chronic acute illness unstable medical condition could confound result safety assessment , increase risk subject lead difficulty comply protocol . 5 . Subject currently consider suicide risk , previously make suicide attempt prior history , currently , demonstrate active suicidal ideation . 6 . Subject female pregnant lactating . 7 . Subject glaucoma . 8 . Subject clinically significant ECG Visit 8 antecedent study ( SPD489325 ) clinically significant laboratory abnormality Visit 7 antecedent study ( SPD489325 ) . 9 . Subject document allergy , hypersensitivity , intolerance amphetamine . 10 . Subject recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) criterion . 11 . Subject history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis know family history Tourette 's Disorder . 12 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . 13 . Subject know family history sudden cardiac death ventricular arrhythmia . 14 . Subject take medication exclude . 15 . Subject take medication central nervous system ( CNS ) effect , affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor ( within 14 day investigational medicinal product administration ) . Stable use bronchodilator inhaler exclusionary . 16 . Subject document allergy , hypersensitivity , intolerance excipients investigational medicinal product ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>